On Tuesday, AEterna Zentaris Inc. (USA) (NASDAQ:AEZS)’s shares declined -4.35% to $0.0572.
AEZS has beta value of 1.76. The company has the market capitalization of $38.04 million. Return on assets ratio of the company was -56.60% while its return on equity ratio was -246.80%. ATR value of company was 0.01 while stock volatility for week was 18.08% while for month was 15.14%.
The mean estimate for the short term price target for AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) stands at $1.23 according to 4 Analysts. The higher price target estimate for the stock has been calculated at $2.00 while the lower price target estimate is at $0.15.
Analysts mean recommendation for the stock is 2.30. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company engaged in developing treatments in oncology, endocrinology and women’s health.
Wayfair Inc (NYSE:W)’s shares dropped -14.01% to $39.42.
W is currently valued at $3.84 billion. The company has 43.28 million shares outstanding. The company has 1.99 value in price to sale ratio while price to book ratio was recorded as -12.36. The company exchanged hands with 7.94 million shares as compared to its average daily volume of 933,617 shares.
The mean estimate for the short term price target for Wayfair Inc (NYSE:W) stands at $51.00 according to 9 Analysts. The higher price target estimate for the stock has been calculated at $60.00 while the lower price target estimate is at $44.00.
Analysts mean recommendation for the stock is 2.00. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Wayfair Inc. (Wayfair) is an online destination for the home. Through its e-commerce business model, the Company offers browsing, merchandising, product discovery and prices for over seven million products from over 7,000 suppliers across five brands: Wayfair.com, Joss & Main, AllModern, DwellStudio and Birch Lane.
At the end of Tuesday’s trade, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)‘s shares dipped -1.47% to $107.24.
ALNY offered -33.60% EPS for prior five years. The company has -15.80% return on equity value while its ROI ratio was -39.00%. The company has $9.21 billion market capitalizations and the institutional ownership was 78.90%. Its price to book ratio was -6.42. Volatility of the stock was 6.92% for the week while for the month booked as 7.56%.
The mean estimate for the short term price target for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stands at $142.09 according to 11 Analysts. The higher price target estimate for the stock has been calculated at $184.00 while the lower price target estimate is at $107.00.
Analysts mean recommendation for the stock is 1.90. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics based on its ribonucleic acid interference (RNAi).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.